X
FDA panel backs J&J’s potential depression blockbuster
https://pharmaphorum.com/news/fda-panel-backs-jjs-potential-depression-blockbuster/
depression
J&J files esketamine nasal spray antidepressant in US
Drug targets 30% of people who don’t respond to approved treatments
Mixed phase 3 results from J&J’s esketamine depression drug
Drug missed efficacy endpoint in older population
Allergan and Gedeon Richter set to expand use of bipolar drug
Companies want Vraylar as option bipolar depression
Takeda depression app impresses in pilot study
App corresponds with standard cognitive and patient-reported assessment measures.
1 2
